For someone hearing about the Vitamin D3 Anti-Inflammatory Regimen for cluster headache for the first time, the loading phase can sound overwhelming. A cumulative 600,000 IU over 6 or 12 days for episodic CH looks enormous on paper, especially when most people are only familiar with daily doses of a few hundred to a few thousand IU.

However, bolus dosing is not unusual in clinical practice. Starship Children’s Hospital in Auckland provides vitamin D3 supplementation recommendations that illustrate this point clearly. When deficiency is suspected or when a child is considered at risk, routine 25(OH)D testing is often unnecessary, and supplementation can be started immediately if there are no contraindications. In cases where daily adherence is unlikely, their guideline even allows for a single annual 600,000 IU dose for children aged five years and older. This high-dose, one-time strategy is known as stoss therapy.

The interesting comparison is not that Starship is a definitive authority for CH, but rather that the dose itself is not unusual. The Vitamin D3 Anti-Inflammatory Regimen uses the same total loading amount as the stoss protocol (600,000 IU), but applies it very differently. Instead of one large bolus, the regimen divides the 600,000 IU across 6 or 12 days. This staged approach quickly elevates serum 25(OH)D while maintaining excellent tolerability in the CH community.

The other key distinction is what follows the loading phase. The cluster headache protocol immediately transitions into a maintenance dose of 10,000 IU daily (adjusted as needed) to keep serum 25(OH)D in the approximate range of 80 to 100 ng/mL. This appears to be the “sweet spot” where the greatest prophylactic benefit is observed. Some patients may require slightly higher levels to achieve a therapeutic response, and from a physiological standpoint this remains achievable with relative safety.

A conservative rule of thumb from bolus-dosing literature is that every 100,000 IU of Vitamin D3 raises serum 25(OH)D by about 10 ng/mL. Given that clinically significant hypercalcemia in most individuals does not manifest until serum levels exceed roughly 200 ng/mL, there is a wide margin between the therapeutic range for CH and the threshold at which toxicity becomes a concern. This is one of the reasons the patient-led regimen has been used successfully and safely by thousands of sufferers worldwide.

You can read the Starship guideline here:
https://www.starship.org.nz/guidelines/vitamin-d-deficiency-investigation-and-management/

The message isn’t to be nonchalant nor to suggest anyone should be casual or careless in their approach to supplementation. If you choose to begin the regimen, do so by following the steps laid out in the Quick Start and Full Reference Guides. Both are available on the main page of www.vitamindregimen.com or in the downloads section. Implementing the protocol correctly gives you the best chance of achieving therapeutic serum levels, maintaining safety, and, importantly, reclaiming your life from this brutal condition.

If you live with cluster headache and haven’t explored the Vitamin D3 Anti-Inflammatory Regimen, you’ll find detailed protocols, safety notes, and real-world experiences at:
www.vitamindregimen.com

Study Overview

This retrospective study evaluated 95 adults with chronic forms of psoriasis treated for up to twelve months using individualised daily doses of vitamin D3 ranging from 30,000 to 60,000 IU per day. All participants discontinued immunosuppressants, corticosteroids, biologics, and phototherapy during the study period, allowing for an isolated assessment of vitamin D3’s effects.

At baseline, 65 percent of patients were vitamin D deficient, with serum 25-hydroxyvitamin D 25(OH)D levels below 30 ng/mL. Within this group, almost 40 percent had levels under 20 ng/mL, representing severe deficiency.

Dosing was stratified by body weight: 30,000 IU per day for individuals between 60 and 75 kg and 40,000 IU per day for those above 75 kg. For patients with 25(OH)D below 20 ng/mL, a loading dose of 600,000 IU administered over ten days (60,000 IU per day) was used before transitioning to daily dosing in close similarity to the 600,000 IU loading dose used for episodic CH upon commencement of the anti-inflammatory regimen. Those with levels between 20 and 29 ng/mL received a 300,000 IU load across five days. Importantly, dosing was adjusted according to parathyroid hormone (PTH) suppression and ionised calcium values rather than 25(OH)D levels alone, a protocol designed to correct vitamin D resistance frequently observed in autoimmune conditions and a foundational premise of the Coimbra protocol.

Clinical Findings

After twelve months, mean PASI (Psoriasis Area and Severity Index) scores improved from 17.83 to 6.52, with 77 percent of participants achieving at least a 50 percent reduction and over 50 percent surpassing 75 percent improvement. Serum 25(OH)D concentrations rose above 100 ng/mL across the cohort, while PTH levels fell from a mean of 52.5 pg/mL to 32.5 pg/mL.

Ionised calcium remained within normal limits throughout, and no cases of hypercalcemia, renal dysfunction or vitamin D toxicity were observed, even in patients receiving up to 60,000 IU per day for several months. This outcome strongly reinforces that when therapy is guided by calcium and PTH monitoring, vitamin D3 can be administered safely at doses far above conventional recommendations.

Why This Matters to Cluster Headache Patients

For cluster headache sufferers using or exploring the Vitamin D3 Anti-Inflammatory Regimen, this study carries particular relevance. The loading protocol in Mahtani’s cohort, 600,000 IU over ten days for patients below 20 ng/mL, is nearly identical to the 600,000 IU loading schedule used in the cluster headache protocol for episodic CH.

However, the key difference lies in maintenance dosing. While the standard CH regimen typically prescribes 10,000 IU per day (or 50,000 IU per week), Mahtani’s patients required 25,000 to 45,000 IU per day on average, with some maintained at 50,000 IU per day for several months before tapering.

For CH patients, this context is highly reassuring. Doses between 10,000 and 20,000 IU per day, often perceived as “high,” are, in reality, modest compared to doses safely employed in other inflammatory diseases such as the Coimbra and LGS protocol. In the psoriasis cohort, even substantially higher doses produced no renal impairment when guided by PTH and calcium monitoring.

Reassessing “High” Doses

In the CH community, many patients are initially anxious about taking 10,000 IU per day, fearing it exceeds safe limits. Yet the Mahtani data make clear that 10,000 IU per day is at the lower end of an established therapeutic range for chronic inflammatory conditions. Even doses four to five times higher have been administered safely under appropriate laboratory oversight. For those with refractory CH who require escalation beyond 10,000 IU per day to achieve PTH suppression and sustained remission, this study provides strong, independent clinical evidence that such dosing can be physiologically tolerated long term.

Conclusion

Mahtani’s 2025 study represents a significant contribution to the broader understanding of vitamin D3’s therapeutic potential. It demonstrates that high-dose daily supplementation, when tailored by individual responsiveness rather than arbitrary limits, can be both effective and safe in chronic immune-mediated disease. For CH patients following the Vitamin D3 Anti-Inflammatory Regimen, it offers an additional layer of reassurance. Both the loading and maintenance strategies align closely with those used in psoriasis but at generally lower doses.

Rather than viewing 10,000 IU per day as excessive, regimen users can take confidence that this amount sits well within a physiologically validated range, and that even higher titrations, if needed for complete CH remission, are safe when done under medical supervision with the appropriate monitoring of labs.

Mahtani R., Singh S., Nair P. M., Singh S. P., Goyal M. (2025). Prolonged high dose daily oral vitamin D3 in the management of psoriasis: A retrospective chart analysis. IP Indian Journal of Clinical and Experimental Dermatology, 11(3), 288-296. https://doi.org/10.18231/j.ijced.89447.1758864688